Ratings Kinnevik AB London S.E.

Equities

0RGZ

SE0022060513

Real-time Estimate Cboe Europe Other stock markets 04:59:02 2024-06-27 am EDT			5-day change	1st Jan Change
90.1 ^SEK	-79.52%		+343.55%	+312.01%

Jun. 14	Enveda Therapeutics, Inc. announced that it has received $55 million in funding from a group of investors	CI
Jun. 05	Kinnevik AB Approves Extra Distribution	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

With an expected P/E ratio at 39.83 and 16.83 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Investment Holding Companies

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
KINNEVIK AB	+312.01%	2.36B		-
INVESTOR AB	+24.41%	83.59B		A-
INVESTMENT AB LATOUR	+9.34%	17.41B	-	C+
KOÇ HOLDING	+55.78%	16.75B		A
AB INDUSTRIVÄRDEN	+9.03%	14.63B	-	C-
L E LUNDBERGFÖRETAGEN AB	-3.87%	12.32B	-	C
BAJAJ HOLDINGS & INVESTMENT LIMITED	+10.21%	11.34B	-	D
HAL TRUST	-1.05%	10.9B		-
MERITZ FINANCIAL GROUP INC.	+26.06%	9.85B		-
GROUPE BRUXELLES LAMBERT SA	-5.50%	9.24B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes